Biodesix, Inc. (BDSX)

Over the past six months, Biodesix's stock price has experienced significant volatility. As of November 19, 2025, the share price was $6.90, representing a decline of 71.01% over the past year. However, more recently, the stock has shown some positive movement, increasing by 29.30% in the past month and 31.57% over the past three months as of August 15, 2025. Biodesix reported strong Q2 2025 financial results with total revenue of $20.0 million, up 12% year-over-year, and an 80% gross margin. The company reported a Q3 loss but topped revenue estimates, with EPS of ($1.16) against an expected ($1.60) and revenue of $21.77 million against an expected $20.98 million. In the past three months, Biodesix insiders have significantly bought more company stock than they have sold, indicating notable insider conviction.

While specific detailed information on demand seasonality for Biodesix, Inc.'s products and services is not explicitly provided, there is a mention of "BDSX Seasonality" which suggests that there might be historical seasonal trends in the stock's performance, which could indirectly relate to demand for its products and services. The company's focus on lung diseases, including lung cancer, might imply some stability in demand, as these are generally not highly seasonal conditions.

Biodesix, Inc., headquartered in Louisville, Colorado, is a commercial-stage molecular diagnostics company specializing in blood-based tests for lung diseases, including lung cancer. The company integrates proteomic and genomic technologies to offer noninvasive testing solutions. Its major products and services include VeriStrat, a proteomic test for NSCLC patients; GeneStrat, an NGS assay for genomic mutations; Nodify Lung Nodule Risk Assessment testing, which includes Nodify XL2 and Nodify CDT tests; IQLung testing strategy, encompassing GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests; and Biopharma Services, partnering with companies for diagnostic solutions.

Biodesix, Inc. primarily serves healthcare providers and pharmaceutical partners in the United States. The company is also pursuing collaborations to expand its customer base in Europe and Asia. Its headquarters are located in Louisville, Colorado, U.S.

In the past year, Biodesix has maintained a generally positive brand reputation among analysts, with a consensus rating of "Moderate Buy". The average twelve-month price objective among analysts is $32.50. The company's strong Q2 and Q3 2025 financial results, including significant year-over-year revenue growth and improved gross margins, have contributed positively to its reputation. Biodesix's expansion into primary care for lung nodule management, the exploration of radiomics and digital diagnostics, and the development of a new Minimal Residual Disease (MRD) test demonstrate a forward-looking approach and commitment to innovation. The expanded partnership with Bio-Rad for developing advanced cancer diagnostics using ddPCR technology also reflects positively on the company's collaborative efforts and technological advancements. Wall Street Zen upgraded Biodesix from a "sell" to a "hold" rating in November 2025.

Ownership of Biodesix, Inc. is distributed among institutional, individual (insider), and retail investors. Insiders hold a significant portion of the stock, with approximately 30.1% of the company owned by insiders. Major individual insider shareholders include Lawrence T. Kennedy Jr., Matthew Strobeck, and Jack W. Schuler. Major institutional owners and shareholders include Telemark Asset Management LLC, Vanguard Group Inc., and Monashee Investment Management LLC.